ライフサイエンスコーパス: monotherapy

1 (hereafter, the non-BEV group with lomustine monotherapy).

2 es), and survival to 51.5 d (P <= 0.0251 vs. monotherapies).

3 omes between intermittent and continuous ADT monotherapy.

4 idual prostaglandin analogues in patients on monotherapy.

5 ients were successfully weaned to belatacept monotherapy.

6 erm clinical outcomes compared with olaparib monotherapy.

7 enolate mofetil and maintained on tacrolimus monotherapy.

8 al diagnosis (low risk) received vinblastine monotherapy.

9 ransplants were then performed using PRCL-02 monotherapy.

10 vity is required for sensitivity to CHK1i as monotherapy.

11 ve a robust tumour response to pembrolizumab monotherapy.

12 II trials of immune checkpoint inhibitors as monotherapy.

13 tion of patients for treatment with CHK1i as monotherapy.

14 were analyzed to determine efficacy of LCSD monotherapy.

15 stigate the antidepressant efficacy of piTBS monotherapy.

16 m cell transplantation (SCT) and vinblastine monotherapy.

17 ritical when potentially considering LCSD as monotherapy.

18 treatment was similar to that of olanzapine monotherapy.

19 ents who used azathioprine or tocilizumab as monotherapy.

20 reaks, and mitotic catastrophe compared with monotherapy.

21 etermine the efficacy of fluoroquinolones as monotherapy.

22 V metronidazole and vancomycin vs vancomycin monotherapy.

23 reviously reported for these agents given as monotherapy.

24 s, and piperacillin-tazobactam as definitive monotherapy.

25 mproved disease control compared with either monotherapy.

26 ulti-site, ongoing clinical trial of lithium monotherapy.

27 ences of the infection frequently follow ART monotherapy.

28 nique relative to that of either constituent monotherapy.

29 nd earlier treatment time-points than either monotherapy.

30 ntrolled and are aggravated by valproic acid monotherapy.

31 tients where the LCSD served as stand-alone, monotherapy.

32 Furthermore, many tumors show resistance to monotherapies.

33 rosis in comparison with tumors treated with monotherapies.

34 is in an ovarian allograft model compared to monotherapies.

35 , offering superior safety and efficacy over monotherapies.

36 rs (ICIs) relative to their effectiveness as monotherapies.

37 lack of interpretability and their focus on monotherapies.

38 tients randomized to treatment with colistin monotherapy (10/106, 9.4%) versus patients randomized to

39 ual number of cases (n = 16) were put on MIL monotherapy (100 mg/day for 90 days) or MIL and LAmB com

40 y included 2114 patients (dual therapy, 993; monotherapy, 1121); 23% met the primary outcome.

41 Interventions included monotherapies (134 trials), add-on to metformin-based th

42 igned patients (1:1:1) to receive durvalumab monotherapy (1500 mg) administered intravenously every 4

43 combination with ranibizumab (0.5 mg), or as monotherapy (2 mg).

44 -ineligible patients who received anti-PD-L1 monotherapy(2).

45 therapy after the index diagnosis: (1) drug monotherapy, (2) combination drug therapy, (3) glaucoma

46 Patients were treated with steroid monotherapy (28.9% of cases), NSAID monotherapy (62.2%),

47 ly treated advanced NSCLC received nivolumab monotherapy (3 mg/kg every 2 weeks).

48 hed the clinical benefits of olaparib tablet monotherapy (300 mg twice daily) over chemotherapy treat

49 erved between the 2 treatment arms (colistin monotherapy 6/128 [4.7%] vs combination therapy 12/121 [

50 steroid monotherapy (28.9% of cases), NSAID monotherapy (62.2%), or a combination of both (8.9%).

51 graphically, to once-daily upadacitinib oral monotherapy 7.5, 15, or 30 mg or placebo.

52 In patients receiving OPT-302 monotherapy, 7 of 13 (54%) did not require rescue anti-V

53 reatment arms: 8, 16, or 24 mg of moxidectin monotherapy; 8, 16, or 24 mg of moxidectin plus 400 mg o

54 umab (95% CI 87-96%), 87% with acalabrutinib monotherapy (81-92%), and 47% with obinutuzumab-chloramb

55 risk, 0.55 [0.37-0.83]), or P2Y12 inhibitor monotherapy (absolute risk difference, -3.7 incident cas

56 3]), and short-term DAPT followed by aspirin monotherapy (absolute risk difference, -6.1 incident cas

57 AMD bevacizumab, ranibizumab and aflibercept monotherapies accrue considerable financial, ROIs to pat

58 Vinblastine monotherapy achieved cure in patients with late relapse;

59 Monotherapy activity in murine xenograft models was obse

60 Patients were offered weaning to belatacept monotherapy after 1 year and followed for 5 years.

61 mpared with patients treated with daptomycin monotherapy after adjusting for confounding variables us

62 rol group could receive open-label veliparib monotherapy after disease progression.

63 with intermediate risk receiving vinblastine monotherapy after the amendment experienced relapse agai

64 apy or followed by sorafenib, with sorafenib monotherapy among patients with advanced HCC.

65 trial of antifungal treatment (amphotericin monotherapy, amphotericin with flucytosine, or amphoteri

66 riple therapies in TRULIGHT; and 16 received monotherapies and 16 received triple therapies in MONCAY

67 nsiveness to human tumors, was exposed to 21 monotherapies and combination therapies.

68 d the tyrosine kinase inhibitor dasatinib as monotherapies and in combination.

69 Three monotherapies and one combination were found to be activ

70 pembrolizumab have demonstrated efficacy as monotherapy and are playing an increasingly prominent ro

71 dance on diagnosis, assessment, selection of monotherapy and combination pharmacologic options, and a

72 In contrast, for PCV eyes, anti-VEGF monotherapy and combination therapy with PDT yielded com

73 001) and 10.8 logMAR letters (P < 0.001) for monotherapy and combination therapy, respectively.

74 s report is the first of an ATR inhibitor as monotherapy and combined with carboplatin.

75 ry DNA damage responses through ATM loss) as monotherapy and combined with DNA-damaging drugs such as

76 eizures and demand careful choice of initial monotherapy and continuous neuropsychiatric evaluation o

77 ls at 1 week after the treatment compared to monotherapy and control group (p < 0.01).

78 CH5126766 used as a monotherapy and in combination regimens warrants further

79 , enfortumab vedotin has been evaluated as a monotherapy and in combination with a checkpoint inhibit

80 afts of endocrine-resistant breast cancer in monotherapy and in combination with fulvestrant.

81 ften requires drug combinations (rather than monotherapy) and N-of-one customization.

82 TTP was extended to 47.5 d (P <= 0.0199 vs. monotherapies), and survival to 51.5 d (P <= 0.0251 vs.

83 zumab, 25 (14%) patients given acalabrutinib monotherapy, and 14 (8%) patients given obinutuzumab-chl

84 ients were assigned to receive acalabrutinib monotherapy, and 177 patients were assigned to receive o

85 4 letters for AMD, 17.1 letters for PCV with monotherapy, and 35.5 letters for PCV with combination t

86 owever, many African settings treat with FLU monotherapy, and the cost-effectiveness of adding 5FC to

87 As a monotherapy, and to a greater extent as a combination wi

88 of ischemic and bleeding events, ticagrelor monotherapy appeared to be beneficial after percutaneous

89 gg reduction rates against hookworm than the monotherapy arms.

90 About half of patients received monotherapy as 2 L chemotherapy for advanced/metastatic

91 e associated with longer OS under anti-PD-L1 monotherapy as compared to chemotherapy, reflecting the

92 e CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with pr

93 Those treated with MIL monotherapy attained clinical cure with a gradual decrea

94 were subsequently treated with TG as rescue monotherapy between 2003 and 2019 at three hospitals in

95 lizumab plus bevacizumab; 59 to atezolizumab monotherapy) between May 18, 2018, and March 7, 2019.

96 LSD1 inhibition is ineffective as monotherapy but demonstrates synergy with inhibitors of

97 ys which was prolonged compared with PRCL-02 monotherapy but not compared with the tacrolimus-treated

98 r reduction in body weight and fat mass than monotherapies by promoting negative energy balance.

99 system, the cumulative effects of sequential monotherapies can resemble the effects of a concurrent c

100 t have displayed modest clinical activity in monotherapy cancer trials.

101 Compared with cladribine monotherapy, CDAR led to brief grade 3/4 thrombocytopeni

102 a framework for quickly translating existing monotherapy cell line data into clinically meaningful pr

103 s after PCI with continued P2Y(12) inhibitor monotherapy compared with traditional dual antiplatelet

104 acalabrutinib-obinutuzumab and acalabrutinib monotherapy, compared with obinutuzumab-chlorambucil (me

105 nts or event severity showed that ticagrelor monotherapy consistently reduced ischemic and bleeding e

106 Surgical monotherapy continues to be appropriate for selected pat

107 S-TA and aflibercept (active) or aflibercept monotherapy (control), and assessed over 24 weeks.

108 At 6 months after CDAR versus cladribine monotherapy, CR rates were 100% versus 88% (P = .11), MR

109 dict the efficacy of drug combinations using monotherapy data from high-throughput cancer cell line s

110 rcutaneous coronary intervention, ticagrelor monotherapy demonstrated a 6% risk reduction, compared w

111 Lonafarnib monotherapy did not improve bone or cartilage parameters

112 drug add-ons to recommend when metformin in monotherapy does not achieve the therapeutic goals.

113 ruginosa bacteremia treated with beta-lactam monotherapy during 2009-2015.

114 randomized to either bivalirudin or heparin monotherapy during percutaneous coronary intervention, w

115 GDC or siKRAS monotherapy each impede downstream signaling, leading to

116 nhibitor BAY 1895344, which exhibited strong monotherapy efficacy in cancer xenograft models that car

117 First-line pembrolizumab monotherapy exhibited promising anti-CSCC activity, with

118 58.3% of patients (2109/3620) who began drug monotherapy experienced no further treatment modificatio

119 Ipilimumab (anti-CTLA-4) or anti-PD-1/PD-L1 monotherapy failed to show a significant benefit.

120 2) (n = 6) alone, or with initial tacrolimus monotherapy followed by gradual conversion at 3 weeks to

121 lysis did not show superiority of ticagrelor monotherapy following one-month dual antiplatelet therap

122 ng bevacizumab, ranibizumab, and aflibercept monotherapies for neovascular age-related macular degene

123 , followed by adjuvant intravenous nivolumab monotherapy for 1 year (240 mg every 2 weeks for 4 month

124 b versus adalimumab as first-line biological monotherapy for 52 weeks in patients with active psoriat

125 re presenting our early experience with LCSD monotherapy for carefully selected patients with LQTS.

126 vents while on beta-blockers, LCSD as 1-time monotherapy for certain patients with LQTS requires furt

127 therapeutic effects, we tested PEAMOtecan as monotherapy for efficacy in a mouse orthotopic glioma mo

128 istance, underscoring the safety of rifampin monotherapy for latent tuberculosis.

129 tamines or INCS may be offered as first-line monotherapy for NAR.

130 AFM13 have demonstrated signs of efficacy as monotherapy for patients with R/R HL and the combination

131 for patients with multiple myeloma and as a monotherapy for patients with relapsed and/or refractory

132 corticosteroids (INCS) remain the preferred monotherapy for persistent AR, but additional studies su

133 his prospective phase 2 trial of daratumumab monotherapy for the treatment of AL amyloidosis was desi

134 itreal aflibercept compared with aflibercept monotherapy for treatment of diabetic macular edema (DME

135 mg/kg of nivolumab every 2 weeks), nivolumab monotherapy group (3 mg/kg of intravenous nivolumab ever

136 y longer in the combination group versus the monotherapy group (470.4+/-45.0 ms versus 453.3+/-37.0 m

137 months (95% CI 10.4-17.3) in the durvalumab monotherapy group (n=209) versus 12.1 months (10.4-15.0)

138 2) eye drops three times per day whereas the monotherapy group was treated only with FND.

139 bevacizumab group; none in the atezolizumab monotherapy group) and proteinuria (in two [3%] patients

140 treated with chloroquine/hydroxychloroquine (monotherapy group) versus those treated with combination

141 bevacizumab group; none in the atezolizumab monotherapy group).

142 nd 6.7 months (4.2-8.2) for the atezolizumab monotherapy group, median progression-free survival was

143 detected in a single animal in the rifampin monotherapy group.

144 up and two (3%) patients in the atezolizumab monotherapy group.

145 m-based chemotherapy (group A), atezolizumab monotherapy (group B), or placebo plus platinum-based ch

146 lly with tacrolimus and converted to PRCL-02 monotherapy had a mean graft survival of 35.3 days which

147 Bevacizumab monotherapy had an individual, 11-year $14,772 treatment

148 Oral miltefosine in monotherapy has proven high efficacy in CL caused by L.

149 NSAIDs showed no added benefit over steroid monotherapy (HR 1.11, 95% CI 0.68-1.80, P = .674).

150 ore significantly inhibits tumor growth than monotherapies (i.e., PDT or RT).

151 carboplatin and paclitaxel, and continued as monotherapy if carboplatin and paclitaxel were discontin

152 ctive platinum doublet, with continuation as monotherapy if the doublet were discontinued, resulted i

153 Half (51.8%) received monotherapy in 2 L, of whom 69.0% received taxanes.

154 herefore, we compared bivalirudin to heparin monotherapy in a contemporary cohort of such patients.

155 the erythroid response compared with either monotherapy in a qualitative and quantitative manner.

156 stablish the clinical outcomes of enasidenib monotherapy in a subgroup of patients with myelodysplast

157 ssess the efficacy and safety of abrocitinib monotherapy in adolescents and adults with moderate-to-s

158 ive multicenter phase 2 study of daratumumab monotherapy in AL (NCT02816476).

159 Additionally, we confirmed STING-NP monotherapy in an additional melanoma (YUMM1.7) and brea

160 r dermatological autoimmunity and anti-PD-L1 monotherapy in bladder cancer.

161 ty of the CHK1 inhibitor (CHK1i) prexasertib monotherapy in BRCA wild-type (BRCAwt) HGSOC patients.

162 uncture and hypnotherapy may have benefit as monotherapy in functional heartburn, or as adjunctive th

163 types predict survival response to anti-VEGF monotherapy in glioblastoma.

164 gonist CCX872 increased median survival as a monotherapy in KR158 glioma-bearing animals and further

165 This trial evaluated oral NSI-189 as monotherapy in major depressive disorder.

166 rated and exhibited efficacy as a short-term monotherapy in participants with HIV-1.

167 dverse events during maintenance daratumumab monotherapy in patients in the D-VMP group were respirat

168 pembrolizumab plus axitinib versus sunitinib monotherapy in patients with advanced renal cell carcino

169 adding rivaroxaban 2.5 mg twice daily to ASA monotherapy in patients with chronic vascular disease in

170 (LAMA) combination therapy over LABA or LAMA monotherapy in patients with COPD and dyspnea or exercis

171 ed safety and clinical activity of avadomide monotherapy in patients with de novo R/R DLBCL and trans

172 Daratumumab showed encouraging efficacy as monotherapy in patients with heavily pretreated multiple

173 s being evaluated for efficacy and safety as monotherapy in patients with mild to moderate Alzheimer'

174 tive biomarker for response to pembrolizumab monotherapy in patients with previously treated recurren

175 ne safety and tolerability of iadademstat as monotherapy in patients with relapsed/refractory acute m

176 ssed the safety and efficacy of satralizumab monotherapy in patients with the disorder.

177 of a pivotal multicenter trial of ibrutinib monotherapy in previously treated patients with Waldenst

178 permits control of rejection with belatacept monotherapy in selected patients.

179 However, to date, ICB monotherapy in such malignancies has been ineffective.

180 f cardiovascular events as compared with ASA monotherapy in the COMPASS trial (Cardiovascular Outcome

181 nventional 12-month DAPT followed by aspirin monotherapy in the reduction of the primary composite en

182 hese transformable peptides can be used as a monotherapy in the treatment of HER2(+) breast cancer.

183 rategy with either bivalirudin or heparin as monotherapy in this patient group.

184 f pembrolizumab plus axitinib over sunitinib monotherapy in treatment-naive, advanced renal cell carc

185 oma progression more effectively than either monotherapy in vivo and in vitro.

186 cles (28 days each), followed by tafasitamab monotherapy (in patients with stable disease or better)

187 Modeling HBsAg kinetics during REP 2139-Ca monotherapy indicates a short HBsAg half-life (1.3 days)

188 and subsequent patients received vinblastine monotherapy instead.

189 three time points (initiation of noninsulin monotherapy, intensification to noninsulin combination t

190 Daratumumab monotherapy is associated with deep and rapid hematologi

191 Although beta-lactam monotherapy is common, data to guide the choice between

192 Left prefrontal piTBS monotherapy is effective for the treatment of recurrent

193 udied to treat solid tumors, but its use for monotherapy is limited due to incomplete tumor eradicati

194 ts, the antithrombotic potency of ticagrelor monotherapy is similar to that of ticagrelor plus ASA wi

195 4 weeks' follow-up compared with aflibercept monotherapy, is well tolerated and shows modest anatomic

196 silico: (i) HAP and ionising radiation (IR) monotherapies may attack tumours in dissimilar, and comp

197 ability of malaria parasites to survive ART monotherapy may relate to an innate growth bistability p

198 DAPT followed by aspirin or P2Y12 inhibitor monotherapy; midterm (6-month) DAPT; 12-month DAPT; and

199 chronic HEV infection treated with ribavirin monotherapy (N = 255), to identify the predictive factor

200 caling and root planing (SRP) to receive ERL monotherapy (n = 27) or MIST (n = 26).

201 repetitive transcranial magnetic stimulation monotherapy (n = 35), or sham stimulation (n = 35).

202 igned randomly to one of three groups: piTBS monotherapy (n = 35), repetitive transcranial magnetic s

203 se randomly assigned to active NeuroStar TMS monotherapy (n = 48) or sham TMS (n = 55) for 30 daily t

204 combination with ranibizumab (n = 23) or as monotherapy (n = 8).

205 rolizumab plus axitinib (n=432) or sunitinib monotherapy (n=429).

206 AC cases do not harbor a durable response to monotherapy of CDK4/6 inhibitor.

207 Radical prostatectomy, as a primary monotherapy, offers the potential benefits of avoiding A

208 PRCL-02 monotherapy only marginally prolonged graft survival (MS

209 anipulating compounds have been evaluated as monotherapies or adjunctive treatments for major depress

210 t of heterogeneity might shape the choice of monotherapy or additional combination treatments to targ

211 hereafter, the BEV group; either bevacizumab monotherapy or bevacizumab with lomustine) and those not

212 nts can be more effective than constant-dose monotherapy or combination therapy in vitro.

213 ntify TMPRSS13 as a potential new target for monotherapy or combination therapy with established chem

214 sessed the safety of intravitreal OPT-302 as monotherapy or combined with ranibizumab (Lucentis; Gene

215 whether overall survival (OS) with SIRT, as monotherapy or followed by sorafenib, is noninferior to

216 andomized clinical trials comparing SIRT, as monotherapy or followed by sorafenib, with sorafenib mon

217 zumab, tofacitnib, or ustekinumab, either as monotherapy or in combination (with immunomodulators), t

218 it a durable anti-tumor response either as a monotherapy or in combination with checkpoint inhibitor

219 human anti-BMP6 antibody (KY1070) either as monotherapy or in combination with Darbepoetin alfa on i

220 es for further evaluation as a candidate for monotherapy or in combination with other targeted agents

221 ivering and producing therapeutic agents, as monotherapy or in combination with other therapeutic mod

222 s were treated via IAC with either melphalan monotherapy or melphalan plus topotecan.

223 a 1:1 ratio to receive continued rilonacept monotherapy or placebo, administered subcutaneously once

224 Future studies of ivosidenib monotherapy or rational combination approaches should be

225 r attempts to use oxygenation of tumors as a monotherapy or to improve radiotherapy have failed becau

226 calabrutinib and obinutuzumab, acalabrutinib monotherapy, or obinutuzumab and oral chlorambucil.

227 itinib orally twice daily or 50 mg sunitinib monotherapy orally once daily for 4 weeks per 6-week cyc

228 roaches to analyze the benefit of ticagrelor monotherapy over conventional DAPT.

229 onotherapy was common in Australia (30.0% of monotherapy patients) and Canada (43.8%), but infrequent

230 herapy was observed, with 58% receiving only monotherapy pre-transplant.

231 ination antiretroviral therapy (cART), CPT31 monotherapy prevented viral rebound after discontinuatio

232 of the BRIGHTE study after 8-day functional monotherapy (primary endpoint); here we report planned i

233 lonal antibodies (COV2-2196 or COV2-2381) as monotherapy protected rhesus macaques from SARS-CoV-2 in

234 Rituximab monotherapy (R-Mono) in unselected patients has shown a

235 In chronically infected animals, CPT31 monotherapy rapidly reduced viral load by ~2 logs before

236 tically significant advantage for ticagrelor monotherapy (rate ratio, 0.92 [95% CI, 0.85-0.99; P=0.02

237 can identify patients who will benefit from monotherapy rather than from combinations.

238 animals receiving no treatment or vancomycin monotherapy recovered medians of 1.76 and 2.91 log10 CFU

239 Satralizumab monotherapy reduced the rate of NMOSD relapse compared w

240 short-term DAPT followed by P2Y12 inhibitor monotherapy reduces major bleeding after percutaneous co

241 of aspirin with continued P2Y(12) inhibitor monotherapy reduces risk of bleeding when stopped 1 to 3

242 the elderly between bivalirudin and heparin monotherapy regarding the primary end point (180-day all

243 inuing aspirin in favor of P2Y(12) inhibitor monotherapy remains disputed.

244 While cisplatin monotherapy resulted in tumor cell apoptosis, Rev7 delet

245 g of how the transcriptional response of two monotherapies results in that of their combination.

246 Tazemetostat monotherapy showed clinically meaningful, durable respon

247 Pembrolizumab monotherapy showed durable antitumour activity and manag

248 In this analysis, daratumumab 16 mg/kg monotherapy showed durable responses and there were no n

249 FND cauterization as monotherapy significantly obliterated (lymph)angiogenesi

250 The first included monotherapy studies and studies in which the two drugs u

251 eviously observed in olaparib and durvalumab monotherapy studies.

252 oxic T-lymphocyte antigen-4, and 85 received monotherapy targeting programmed cell death 1 or its lig

253 -day stroke risk was higher in patients used monotherapy than those used DAPT in TIA with positive DW

254 Compared with ASA monotherapy, the combination of rivaroxaban 2.5 mg twice

255 ater therapeutic effects than the respective monotherapies, these strategies may lead to lower dosage

256 ed trial comparing atezolizumab (anti-PD-L1) monotherapy to chemotherapy in bladder cancer.

257 tent ADT has been used as an approach to ADT monotherapy to limit morbidity by enabling cyclical reco

258 sfusion and discuss using first-line IV iron monotherapy to treat anemic patients with cancer, which

259 djusted, analyses were conducted introducing monotherapy type as an independent variable.

260 T was associated with worse survival, as was monotherapy use.

261 metformin-based therapies (296 trials), and monotherapies versus add-on to metformin therapies (23 t

262 In MONCAY, these figures were 12/15 (80%) on monotherapy versus 13/16 (81%) on triple therapy (P = 1.

263 uvant nivolumab plus ipilimumab or nivolumab monotherapy versus a placebo in this patient population.

264 all survival compared between the durvalumab monotherapy versus chemotherapy groups in the population

265 m increased significantly with empagliflozin monotherapy versus placebo (fractional excretion of sodi

266 Awt HGSOC develops resistance to prexasertib monotherapy via a prolonged G2 delay induced by lower CD

267 p<0.0001; and not reached with acalabrutinib monotherapy vs 22.6 months with obinutuzumab, 0.20; 0.13

268 comparative efficacy and safety of biologic monotherapy vs combination therapy with immunomodulators

269 Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding

270 and PCV received 5.5 and 5.3 injections (5.0 monotherapy vs. 5.6 combination therapy; mean, 1.2 PDT s

271 The primary motivation for LCSD monotherapy was an unacceptable quality of life stemming

272 short-term DAPT followed by P2Y12 inhibitor monotherapy was associated with a reduced risk of major

273 Irinotecan monotherapy was common in Australia (30.0% of monotherap

274 Standard anti-epileptic drug monotherapy was ineffective in the patient.

275 Noninsulin monotherapy was initiated earlier in South Asian and bla

276 Type of monotherapy was not significantly associated with mortal

277 Ivosidenib monotherapy was well-tolerated and induced durable remis

278 who achieved mood stabilization with lithium monotherapy, we explored the effect of lithium treatment

279 acizumab, ranibizumab, and aflibercept NVAMD monotherapies were all cost-effective over 11 years, wit

280 or bevacizumab, ranibizumab, and aflibercept monotherapies were compared with ophthalmic and nonophth

281 Animals receiving tacrolimus monotherapy were e on day 100 without rejection.

282 n-Meier curves of TIA patients with DAPT and monotherapy were plotted.

283 of colistin resistance, compared to colistin monotherapy, when given to patients with infections due

284 ll, and nearly 10% received oral artemisinin monotherapy, which is not recommended because of concern

285 ty patients were enrolled; 17 received M6620 monotherapy, which was safe and well tolerated.

286 observed in patients treated with infliximab monotherapy who carried HLA-DQA1*05; conversely the lowe

287 Monotherapy with a P2Y12 inhibitor or aspirin for second

288 In phase-1 clinical studies, monotherapy with a single subcutaneous dose of GS-6207 (

289 In a mouse model of retinitis pigmentosa, monotherapy with a small-molecule RET agonist activates

290 domized, controlled trial comparing colistin monotherapy with colistin-meropenem combination for the

291 h an expected safety profile consistent with monotherapy with each agent.

292 ring canine model of GLD that presymptomatic monotherapy with intrathecal AAV9 encoding canine GALC a

293 received RLT sequentially 4 wk after 3 mo of monotherapy with olaparib.

294 Monotherapy with oral abrocitinib once daily was effecti

295 analysis of dual antiplatelet therapy versus monotherapy with P2Y12 inhibitors in patients after perc

296 se fatality rate among patients who received monotherapy with tetracyclines, chloramphenicol, aminogl

297 However, monotherapy with the nucleic acid polymer REP 2139-Ca is

298 Furthermore, monotherapy with the potent broadly neutralizing antibod

299 dterm or short-term DAPT followed by aspirin monotherapy, with the exception that short-term DAPT fol

300 We performed a prospective trial of SRL monotherapy withdrawal in nonimmune, nonviremic LTRs > 3